Accreditation

TARGET AUDIENCE

This course is directed to physicians specializing in interventional and invasive cardiologists, general cardiologists, cardiovascular surgeons, vascular surgeons, and interventional radiologists.

LEARNING OBJECTIVES

By the conclusion of this activity, participants should be able to:

• Appraise new and upcoming technologies in the management of structural heart disease, including, valvular heart disease, stroke prevention, hemodynamic support, cardiomyopathy and high risk-percutaneous coronary intervention to determine their benefit for patients
• Evaluate the relative advantages and disadvantages of different strategies in complex cases involving valvulardisease
• Present indications, techniques, outcomes, and complications for transcathetervalve intervention in patients with native valvelesions
• Compare FDA approved technologies for TAVR and the scientific data supporting theiruse
• Examine best practice techniques for high certainty valveimplantation
• Analyze data and techniques for treatment of bioprosthetic valvedysfunction
• Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease, and the functionality of the team within a center ofexcellence
• Evoke the changing landscape of percutaneous and surgical techniques of valve repair and replacement
• Evaluate the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgicalinterventions
• Recognize the different diagnostic tools and combinations required to accurately diagnose specific structural heart diseases and plan transcathetertherapy
• Discuss rationale and technique of alternative access approach for aorticstenosis
• Discuss investigational valves in the near horizon including their therapeutic advantages and limitations
• Describe the advantages and pitfalls of comprehensive diagnostic techniques for patients with valvular heart disease such as cardiac computed tomography, three-dimensional echocardiography, and complex invasive hemodynamiccatheterization
• Discuss transcatheter treatment options for mitral valvedisease
• Explain the clinical data supporting mitral valve leaflet clip approximation for the treatment of mitralregurgitation
• Demonstrate and present best practice techniques for mitral valve clipapproximation
• Examine alternative investigational devices for the transcatheter treatment of mitral regurgitation
• Present alternatives with transcatheter aortic and pulmonic valve technologies for the treatment of mitraldisease
• Present progress in transcatheter mitral valvereplacement
• Present the techniques and efficacy of transcatheter treatment of mitral prosthetic valve paravalvularleaks
• Demonstrate how septal ablation and technologies can improve mitral regurgitation in hypertrophic cardiology.
• Discuss transcatheter treatment options for tricuspid valvediseaseExamine the evidence regarding closure of percutaneous closure of patent foramen ovale for stroke prevention.
• Examine the evidence regarding left atrial appendage exclusion for stroke prevention in patients with atrialfibrillation.
• Examinethedataandtechniquesforidentificationandassessmentofhemodynamically significant coronary arterylesions.
• Examine the data and techniques for coronary imaging and lesioncharacterization.Examine the data and techniques regarding new stent and bio-absorbable scaffolds for percutaneous coronary intervention, as well as devices for coronary intervention facilitation (plaque modification, chronic total occlusion).
• Examine the data and techniques for the treatment of in-stent re-stenosis, with emphasizes in new technology.
• Discuss therapeutic alternatives in patients with atrial fibrillation and the data to supportit.
• Identify the indication, techniques and complications for left atrial appendage occlusion in patients with afib.
• Recognize the risks and benefits of anticoagulation in patients with atrial fibrillation and other co-morbidities.
• Identify the role for catheter ablation for patients with atrial fibrillation based on the most recent trial
• Recognize the pathophysiology of atrial fibrillation and potential for new therapeutic targets.
• Learn and evaluate patients for advanced heart failure therapies.
• Focused learning related to multi organ transplant and special heart transplant patient population.
• Evaluation and basic management of patient with mechanical circulatory support devices including LVADs and Total artificial heart.
• Case based scenarios discussing complex advanced heart failure patients.

CME ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Vein & Lymphatic Society (AVSL) and Behind the Scenes, a Medical Education Company, LLC (BTS) . The AVLS is accredited with commendation by the ACCME to provide continuing medical education for physicians.

CME CREDIT DESIGNATION STATEMENT

American Vein and Lymphatic Society designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

• For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit^TM from organizations accredited by the ACCME.
• The American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit^TM from organizations accredited by the ACCME.
• The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the ACCME. Physician assistants may receive a maximum of 18.25 hours of Category 1 credit for completing this program.

UEMS/EACCME CME CREDIT RECOGNITION

The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

DISCLAIMER

Behind the Scenes and the American Vein and Lymphatic Society make every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Behind the Scenes and the American Vein and Lymphatic Society must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an activity sponsored by BTS and AVLS are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Behind the Scenes requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.